Simvastatin ameliorates testosterone-induced prostatic hyperplasia in rats via modulating IGF-1/PI3K/AKT/FOXO signaling
dc.Affiliation | October university for modern sciences and Arts MSA | |
dc.contributor.author | El-Shafei, Nyera H | |
dc.contributor.author | Zaafan, Mai A | |
dc.contributor.author | Kandil, Esraa A | |
dc.contributor.author | Sayed, Rabab H | |
dc.date.accessioned | 2023-05-19T09:18:00Z | |
dc.date.available | 2023-05-19T09:18:00Z | |
dc.date.issued | 2023-05 | |
dc.description.abstract | Benign prostatic hyperplasia (BPH) is characterized by non-malignant enlargement of prostate cells causing many lower urinary tract symptoms. BPH pathogenesis includes androgens receptors signaling pathways, oxidative stress, apoptosis, and possibly changes in IGF-1/PI3K/AKT/FOXO pathway. Altogether, modulating IGF-1/PI3K/AKT/FOXO signaling along with regulating oxidative stress and apoptosis might preserve prostatic cells from increased proliferation. Beyond statins’ common uses, they also have anti-inflammatory, antioxidant, and anti-tumor effects. This study aims to determine simvastatin’s beneficial effect on testosterone-induced BPH. Rats were randomly allocated into four groups, 9 rats each. The control group received olive oil subcutaneously and distilled water orally for 30 consecutive days. The second group received simvastatin (20 mg/kg, p.o.) dissolved in distilled water. The BPH-induced group received testosterone enanthate (3 mg/kg, s.c.) dissolved in olive oil, and the BPH-induced treated group received both simvastatin and testosterone. Testosterone signifi- cantly increased prostate index and severity of histopathological alterations in prostate tissues as well as 5-alpha reductase enzyme level in contrast to simvastatin treatment that reversed the testosterone-induced alterations in these parameters. Likewise, testosterone up-regulated IGF-1/PI3K/AKT signaling pathway and down-regulated FOXO transcription factor. It also decreased apoptotic markers level in prostatic tissue BAX, caspase-3, and caspase-9, while it elevated Bcl-2 level. In addition, it alleviated reduced GSH and GPX5 levels and SOD activity. Simvastatin treatment significantly opposed testosterone’s effect on all aforementioned parameters. In conclu- sion, this study demonstrates that simvastatin is a possible treatment for BPH which may be attributed to its effect on IGF-1/PI3K/AKT/FOXO signaling pathway as well as anti-oxidant and apoptotic effects | en_US |
dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=21333&tip=sid&clean=0 | |
dc.identifier.doi | https://doi.org/10.1016/j.ejphar.2023.175762 | |
dc.identifier.other | https://doi.org/10.1016/j.ejphar.2023.175762 | |
dc.identifier.uri | http://repository.msa.edu.eg/xmlui/handle/123456789/5575 | |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.ispartofseries | European Journal of Pharmacology;950, art. no. 175762. | |
dc.subject | Benign prostatic hyperplasia | en_US |
dc.subject | Simvastatin | en_US |
dc.subject | IGF-1 | en_US |
dc.subject | PI3K | en_US |
dc.subject | AKT | en_US |
dc.subject | FOXO | en_US |
dc.title | Simvastatin ameliorates testosterone-induced prostatic hyperplasia in rats via modulating IGF-1/PI3K/AKT/FOXO signaling | en_US |
dc.type | Article | en_US |